ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs
The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.
- The Series A Shares are convertible, and upon conversion, shall at all times be paid with Ordinary Shares and not in cash.
- Such listing will be either by IPO, backdoor (shell merger) or direct listing or another mutually agreed method.
- The Cantheon investment will be exempt from registration under the applicable U.S. federal and state securities laws, rules and regulations.
- “This financing is a crucial next step in the restructuring of RespireRx and the founding and funding of ResolutionRx.